{"id":"W2949395959","doi":"10.1136/annrheumdis-2019-eular.798","title":"FRI0452 TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DERMATOLOGIC ENDPOINTS FROM 2 PHASE 3 STUDIES","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Tofacitinib; Medicine; Psoriatic arthritis; Dermatology; Arthritis; Rheumatoid arthritis; Psoriasis; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":{"n_in":0,"stratum":"aff_core","weight":5595.2375,"opus":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"Conference abstract reporting dermatologic endpoints of tofacitinib from two phase 3 trials; a clinical efficacy analysis."},"gpt":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"low","reason":"The title identifies a clinical treatment analysis, but the abstract is missing and provides insufficient detail."},"grok":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"Clinical phase-3 dermatologic endpoints for tofacitinib in psoriatic arthritis."}},"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01131515,0.001712036,0.003495786,0.001051239,0.0005291377,0.002167818,0.0008326156,0.001310155,0.001835441],"category_scores_gemma":[0.004576307,0.0005057361,0.006662809,0.001196365,0.0005790739,0.00140513,0.0006146403,0.002452777,0.0003351775],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00114963,"about_ca_system_score_gemma":0.001312509,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006477936,"about_ca_topic_score_gemma":0.00222277,"domain_scores_codex":[0.9961086,0.00223656,0.0002564712,0.0004798791,0.0005755511,0.000342968],"domain_scores_gemma":[0.9956085,0.001736749,0.001405539,0.0004077519,0.0003655547,0.0004758845],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6453113,0.00454008,0.08458637,0.003323753,0.06336448,0.0002560595,0.0002156429,0.005546365,0.01341736,0.00035822,0.004184204,0.1748962],"study_design_scores_gemma":[0.3161623,0.1891219,0.4291984,0.0005795927,0.04282248,0.00119247,0.0002566193,0.004447463,0.004027954,0.00122369,0.01069192,0.0002751953],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9379219,0.05113569,0.001474927,0.0005706891,0.0001967755,0.001077385,0.004473838,0.0001270582,0.003021772],"genre_scores_gemma":[0.983432,0.007536373,0.001154897,0.0008832597,0.0002420508,0.0007999607,0.00513425,0.00004101528,0.0007761605],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01131515,"threshold_uncertainty_score":0,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02667997768072668,"score_gpt":0.2842030658171811,"score_spread":0.2575230881364545,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}